Sorafenib attenuates fibrotic hepatic injury through mediating lysine crotonylation

XF Chen, S Ji - Drug design, development and therapy, 2023 - Taylor & Francis
Background Liver fibrosis is an independent contributor of chronic liver diseases, and
regressing liver fibrosis is considered a potential therapeutic target for chronic liver …
被引用次数：10 相关文章

Sorafenib Attenuates Fibrotic Hepatic Injury Through Mediating Lysine Crotonylation

XF Chen, S Ji - Drug design, development and therapy, 2022 - pubmed.ncbi.nlm.nih.gov
Background Liver fibrosis is an independent contributor of chronic liver diseases, and
regressing liver fibrosis is considered a potential therapeutic target for chronic liver …
[HTML] nih.gov

[HTML][HTML] Sorafenib Attenuates Fibrotic Hepatic Injury Through Mediating Lysine Crotonylation

XF Chen, S Ji - Drug Design, Development and Therapy, 2022 - ncbi.nlm.nih.gov
Background Liver fibrosis is an independent contributor of chronic liver diseases, and
regressing liver fibrosis is considered a potential therapeutic target for chronic liver …

Sorafenib Attenuates Fibrotic Hepatic Injury Through Mediating Lysine Crotonylation

C Xiao-Feng, S Ji - Drug Design, Development and Therapy, 2022 - search.proquest.com
Background: Liver fibrosis is an independent contributor of chronic liver diseases, and
regressing liver fibrosis is considered a potential therapeutic target for chronic liver …

Sorafenib Attenuates Fibrotic Hepatic Injury Through Mediating Lysine Crotonylation

XF Chen, S Ji - Drug Design, Development and Therapy, 2022 - dovepress.com
Background: Liver fibrosis is an independent contributor of chronic liver diseases, and
regressing liver fibrosis is considered a potential therapeutic target for chronic liver …
[PDF] scienceopen.com

[PDF][PDF] Sorafenib Attenuates Fibrotic Hepatic Injury Through Mediating Lysine Crotonylation

XF Chen, S Ji - Drug Design, Development and Therapy, 2022 - scienceopen.com
Background: Liver fibrosis is an independent contributor of chronic liver diseases, and
regressing liver fibrosis is considered a potential therapeutic target for chronic liver …

Sorafenib Attenuates Fibrotic Hepatic Injury Through Mediating Lysine Crotonylation.

XF Chen, S Ji - Drug Design, Development and Therapy, 2022 - europepmc.org
Background Liver fibrosis is an independent contributor of chronic liver diseases, and
regressing liver fibrosis is considered a potential therapeutic target for chronic liver …
[PDF] semanticscholar.org

[PDF][PDF] Sorafenib Attenuates Fibrotic Hepatic Injury Through Mediating Lysine Crotonylation

XF Chen, S Ji - Drug Design, Development and Therapy, 2022 - pdfs.semanticscholar.org
Background: Liver fibrosis is an independent contributor of chronic liver diseases, and
regressing liver fibrosis is considered a potential therapeutic target for chronic liver …